Nexstim Oyj
Research Nexstim Oyj (NXTMH) on Bullrun: market cap EUR 68.01M, P/E 940.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNXTMH
- ExchangeHE
- CountryFinland
- SectorHealthcare
- IndustryMedical Devices
- CurrencyEUR
- Market capEUR 68.01M
- P/E940.0
- Financial periodFY2025
- RevenueEUR 10.97M
- Revenue growth25.6%
- Net incomeEUR 573.20K
- Free cash flow-EUR 37.35K
- Gross margin90.3%
Valuation Snapshot
latest market cap is EUR 68.01M; P/E is 940.0.
Peer valuation comparison
Latest P/E is 940x versus a Healthcare sector median of 24.61x (3719.9% above).
Latest P/E is 940x versus a Finland median of 17.71x (5206.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 10.97M | EUR 573.20K | -EUR 37.35K | 90.3% | 0.08 | EUR 2.68M | EUR 4.13M | EUR 4.18M |
| FY2024 | EUR 8.74M | -EUR 892.29K | EUR 175.43K | 95.9% | -0.13 | EUR 3.86M | EUR 5.36M | EUR 3.70M |
| FY2023 | EUR 7.25M | -EUR 1.33M | -EUR 3.76M | 96.4% | -0.2 | EUR 1.45M | EUR 4.44M | EUR 2.84M |
| FY2022 | EUR 9.53M | EUR 1.31M | -EUR 438.09K | 99.9% | 0.18 | EUR 4.44M | EUR 3.49M | EUR 4.07M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | EUR 68.01M | 940.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Nexstim Oyj
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nexstim Oyj's market cap?
Nexstim Oyj's market capitalization is EUR 68.01M.
What is Nexstim Oyj's P/E ratio?
Nexstim Oyj's price-to-earnings (P/E) ratio is 940.0.
What does Nexstim Oyj do?
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb.